CORPAK Acquires Merck Serono’s UK Gastroenterology Sales and Distribution Operation

Finance Tue, Jul 30, 2013, 12:30 PM EDT – U.S. Markets close in 3 hrs 30 mins Stock Watch CORPAK Acquires Merck Serono’s UK Gastroenterology Sales and Distribution Operation Press Release: Mergers and Acquisitions Tue, Oct 2, 2012 8:00 AM EDT Print Related Content BUFFALO GROVE, IL–(Marketwire – Oct 2, 2012) – CORPAK MedSystems, Inc., a leading developer, manufacturer, and marketer of medical devices for the enteral-feeding and bedside-location markets, today announced it will acquire the gastroenterology sales and distribution operation of Merck Serono Limited in the UK and Ireland. Merck Serono had previously served as CORPAK’s distribution partner for the region. “The acquisition of the Merck Serono gastroenterology business strengthens our presence in Europe and our direct operation will support high levels of customer service and continued growth,” says Tom Kuhn, President of CORPAK. “I would like to thank the employees at Merck Serono for their support in building the CORPAK business in the UK and Republic of Ireland.” “The gastroenterology business is a strong and growing operation in the UK and Ireland, but Merck Serono has made a strategic decision to focus on our core pharmaceutical business,” explains Charles Dring, Commercial Director of Merck Serono Limited. “We have been working very closely with CORPAK to make the transition as seamless as possible for our customers.” There will be no change to the product range and all CORPAK products will continue to be available on the current codes and prices. The acquisition keeps relationships with existing sub-distributors unchanged. “We are especially pleased to be able to welcome the gastroenterology employees from Merck Serono to the CORPAK family,” says Jeff Blair, CEO of CORPAK. “We are confident that the UK and Ireland team will continue the history of excellence and dedication that has benefitted our customers in the past.” “This acquisition represents an important step in expanding our international presence and we look forward to continuing to provide our innovative, quality products to the European market,” added Eric Larson, Chairman of the CORPAK Board. CORPAK MedSystems UK ( ) Tel: +44 (0) 129 380 4769 Fax: +44 (0) 129 380 4770 E-mail: About CORPAK MedSystems, Inc. ( ) CORPAK MedSystems, Inc. is a leading developer, manufacturer, and marketer of innovative medical devices focused on the enteral-feeding and bedside-location markets, including the company’s flagship CORTRAK computer-guided system that enables real-time visualization of the feeding-tube tip during placement. The company has established the leading market position in premium branded, adult, long-term nasogastric feeding tubes and offers a broad portfolio of other high-quality enteral products, including gastrostomy feeding tubes, gastric-pressure relief devices, and enteral-feeding safety devices. Founded in 1979, CORPAK was acquired by Linden Capital Partners in August 2008 from Cardinal Health.


No link between gastric acid-suppressing medications, pneumonia in NSAID users

will provide a $1.5 million unrestricted grant to the AGA Research Foundation endowment. This grant to the AGA Research Foundation endowment funds research and discoveries in gastroenterology, and supports young investigators across the United States. The AGA Research Foundation provides research grants to investigators in gastroenterology and hepatology. The foundation’s grants transform young researchers’ lives by encouraging them to embark on and continue careers in research. Many ultimately make discoveries that improve patient care. Since 1984, the AGA has funded more than 700 scientists. “We are proud to play a role in young investigators’ ongoing research to better understand GI conditions and find innovative approaches to helping people,” said Loren Laine , MD, AGAF, president of the AGA Institute. “Takeda’s support of the AGA Research Foundation is a critical investment in the future of the field of gastroenterology that ensures we can continue funding research into the causes, diagnosis, prevention and treatment of digestive diseases.” “For millions of Americans living with digestive disorders, ongoing research remains vital to expand our understanding of the conditions and hopefully improve outcomes. Generous contributions such as this one from Takeda Pharmaceuticals underscore that commitment,” said David A. Peura , MD, AGAF, past president of the AGA. “With Takeda’s help, we will be able to continue supporting young researchers and investigators across this therapeutic area.” SOURCE American Gastroenterological Association

click to investigate

AGA Research Foundation receives grant for gastroenterology research

Gut. 2013;doi:10.1136/gutjnl-2013-304738. July 26, 2013 Patients taking nonsteroidal anti-inflammatory drugs who also used proton pump inhibitors or histamine-2 receptor antagonists were no more likely to be hospitalized for community-acquired pneumonia than nonusers in a recent study. Researchers performed retrospective cohort studies of eight cohorts of new nonsteroidal anti-inflammatory drug (NSAID) users aged 40 years or older, collected from eight databases throughout the US, UK and Canada (n=4,238,504) as part of the Canadian Network for Observational Drug Effect Studies (CNODES). All patients were prescribed oral NSAIDs between January 1997 and March 2010, with a duration of 28 days or longer. Incidence of hospitalization for community-acquired pneumonia (HCAP) was compared between users and nonusers of proton pump inhibitors (PPIs) or histamine-2 receptor antagonists (H2RAs). PPIs were initiated in 2.3% of the entire cohort (n=96,870), while H2RA analysis included 47,344 exposed and 4,342,733 nonexposed participants. At 6 months of treatment the cumulative incidence of HCAP was 0.17% among PPI users and 0.12% among nonusers. No association was observed between HCAP and PPI use (adjusted OR=1.05; 95% CI, 0.89-1.25) or H2RA use (0.16% among users vs. 0.12% among nonusers; aOR=0.95; 95% CI, 0.75-1.21) after adjustment for confounders. Site-specific ORs for HCAP and PPI us ranged from 0.93 to 1.21, with the exception of data from Nova Scotia (aOR=3.73; 95% CI, 1.12-12.4). Exclusion of the Nova Scotia data yielded similar results to pooled analysis (aOR=1.03; 95% CI, 0.87-1.22). Sensitivity analyses and random-effects meta-analyses also yielded similar results to the primary analyses. Proton pump inhibitors do not appear to increase the risk of HCAP, researcher Kristian Filion, PhD, assistant professor of medicine in the clinical epidemiology division at Jewish General Hospital/McGill University in Montreal, told Clinicians can now reassure their patients that use of PPIs will not increase their pneumonia risk.

pop over here{FE5F9FEF-80FC-4830-BDF9-9F1460DEBDAA}/No-link-between-gastric-acid-suppressing-medications-pneumonia-in-NSAID-users


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: